Ticker LaunchSPAC · Searching for a target · DMII
Drugs Made In America Acquisition II Corp.
Drugs Made In America Acquisition II Corp. (DMII) is a blank-check company (SPAC) that raised $500M in its initial public offering on Sep 25, 2025, listing on Nasdaq Global Market. It has not announced a definitive business combination agreement. Cantor led the IPO. Maples and Calder advised the SPAC and Ellenoff Grossman & Schole advised the underwriters on the IPO.
- Status
- Searching for a target
- Ticker
- DMII
- IPO date
- Sep 25, 2025
- IPO size
- $500M
- IPO exchange
- Nasdaq Global Market
- IPO underwriters
- Cantor
- SPAC counsel (IPO)
- Maples and Calder
- Underwriters' counsel (IPO)
- Ellenoff Grossman & Schole
More on this SPAC for subscribers
- Trust balance and value per share
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- IPO prospectus (424B4) Sep 25, 2025
- All filings on EDGAR CIK 2040475
Other SPAC IPOs from 2025
- Bain Capital GSS Investment Corp.Sep 30, 2025 · $400M
- BTC Development Corp.Sep 30, 2025 · $220M
- Battery Future Acquisition CorpSep 30, 2025
- American Exceptionalism Acquisition Corp. ASep 29, 2025 · $300M
- FutureCrest Acquisition Corp.Sep 26, 2025 · $250M
- Emmis Acquisition Corp.Sep 26, 2025 · $100M